Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.44 |
| ▸ | TK2 | O00142 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29388908 | 0.78 | LMNA (0.49) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL16378861 | 0.78 | LMNA (0.49) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL20643700 | 0.78 | — | — | |
| SCHEMBL27102544 | 0.76 | LMNA (0.34) | TK1TK2LMNASMN1; SMN2 | |
| SCHEMBL27102578 | 0.76 | LMNA (0.34) | TK1TK2LMNASMN1; SMN2 | |
| SCHEMBL23892752 | 0.70 | LMNA (0.45) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL25809594 | 0.70 | TK1 (0.45) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL20463353 | 0.70 | LMNA (0.50) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL2209009 | 0.69 | ADRB1 (0.47) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL4214655 | 0.69 | LMNA (0.49) | TK1TK2LMNASMN1; SMN2ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200207874-A1 | POLYPEPTIDE-POLYNUCLEOTIDE-COMPLEX AND ITS USE IN TARGETED EFFECTOR MOIETY DELIVERY | HOFFMANN-LA ROCHE INC. (US) | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207874-A1 | POLYPEPTIDE-POLYNUCLEOTIDE-COMPLEX AND ITS USE IN TARGETED EFFECTOR MOIETY DELIVERY | PNKP, RNASE1, DCLRE1B | TK1 139/4885TK2 225/4885LMNA 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.